Abstract

In this study, we investigated post-orchiopexy testicular growth of undescended testes (UDTs) at different primary locations and determined the risk factors for testicular atrophy (TA). We conducted a retrospective chart review of boys who had undergone orchiopexy for UDTs during January 2001–December 2013. Patient profile, age at operation, primary UDT location, and testicular volume were noted. TA was defined as ≥50% loss of volume after orchiopexy. The primary endpoints were testicular growth and TA after orchiopexy. The secondary endpoint was risk factors for TA. In total, 182 boys had undergone regular ultrasonography; the median follow-up period was 34 months. Among 230 UDTs, 18 (7.8%) atrophic testicles were identified within a median interval of 13 months after orchiopexy. TA rates were 3.3% (1/30), 6.9% (12/173), and 18.5% (5/27) in primary suprascrotal, canalicular, and above-inguinal UDTs, respectively. The survival probability of UDT was 91%, 92% and 100% when orchiopexy was performed in age ≤1 year, 1 < age ≤2 years, and 100% in age >2 years, respectively. Multivariate analysis revealed that inguinal and above-inguinal UDTs (hazard ratio [HR] 11.76, 95% confidence interval [CI] 1.55–89.33, p = 0.017) and genetic or endocrine disorders (HR 3.19, 95% CI 1.19–8.56, p = 0.021) were the risk factors for TA, but not age at operation, premature birth, and laterality. Thus, TA incidence was higher when patients had high primary testicular locations. Early orchiopexy before two years of age may be associated with higher TA risk, while most testicles have promising growth after orchiopexy.

Highlights

  • Orchiopexy is the standard intervention for congenital undescended testes (UDTs), which is recommended within the age of 6–12 months[1,2,3,4] or in the first 18 months of life[5]

  • We delineated the primary location of UDTs and orchiopexy outcome through ultrasonography follow-up for each testicle

  • The present study was a comprehensive analysis of the testicular growth in patients who had undergone paediatric orchiopexy

Read more

Summary

Introduction

Orchiopexy is the standard intervention for congenital undescended testes (UDTs), which is recommended within the age of 6–12 months[1,2,3,4] or in the first 18 months of life[5]. Orchiopexy decreases the risk of testicular cancer, preserves fertility and improves testicular growth[1,3,4]. Testicular atrophy (TA) is a serious complication when orchiopexy is performed at the recommended age. A comprehensive review of orchiopexy literature reported that the overall risk of TA or nonscrotal positioning was approximately 15% in 19958. In a recent series of 418 orchiopexies performed at a single institution, TA risk was 1.9%9. We reviewed data of patients who had undergone paediatric orchiopexy at our institution by using the appropriate criteria for TA.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call